Scienture Holdings Inc (SCNX) Stock Price, Quote & News

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers

Sector: Healthcare

Phone: 800 261 0281

Website: scienture.com

Address:

6308 Benjamin Rd, Suite 708, Tampa, United States

PoFolks_Capital Oct. 6 at 11:57 PM

$SCNX just get me out of this position without a 50% loss. After that i could careless at this point whether it goes to $100. I dont ever wanna see these 4 letters again unless its with a class action lawsuit attached.

0 · Reply

APEDM Oct. 6 at 10:13 PM

$SCNX https://m.investing.com/news/sec-filings/scienture-holdings-amends-bylaws-to-lower-shareholder-meeting-quorum-93CH-4273967?ampMode=1

0 · Reply

Jhc1114 Oct. 6 at 6:11 PM

$SCNX SCNX’s liquid losartan may sound like innovation, but let’s be real — pharmacies have been compounding liquid versions for years for patients who can’t swallow tablets. Sure, SCNX has an FDA-approved, shelf-stable version that qualifies for insurance coverage. That sounds good on paper. But in practice, the demand is limited, mostly elderly or pediatric patients, and the drug itself is a cheap generic. It’s hard to justify high pricing in such a small, price-sensitive market. This isn’t a breakthrough. It’s a commercial repackaging of something that already exists — with low volume and tight margins. Investors expecting big revenue or stock momentum from this are likely to be disappointed. Don't buy the hype.

0 · Reply

Jhc1114 Oct. 6 at 5:41 PM

$SCNX I always warned whenever scammers promoted this here. So what was the result? A company that's like a cancer should disappear as soon as possible

0 · Reply

Jhc1114 Oct. 6 at 2:43 PM

$SCNX 1. The company offered to repay Arena with shares instead of cash at a conversion price of $2.4861. 2. Arena accepted the loss and agreed to convert, effectively exiting the position. 3. Immediately after, SCNX sold new shares to outside institutions at just $1.20—below market price—to raise cash. However, some scammers are promoting this filing as "good news. Do not invest. Let this company fail.

0 · Reply

Et7806 Oct. 6 at 12:17 AM

$SCNX going to be a good week

0 · Reply

Dharmazen Oct. 5 at 12:28 AM

$SCNX Scienture Holdings amends debenture terms with Arena Investors for share conversion https://www.investing.com/news/sec-filings/scienture-holdings-amends-debenture-terms-with-arena-investors-for-share-conversion-93CH-4271268

0 · Reply

Kickuraston Oct. 3 at 9:04 PM

$SCNX 8-K https://www.sec.gov/ix?doc=/Archives/edgar/data/0001382574/000149315225016882/form8-k.htm

1 · Reply

Orian1978 Oct. 3 at 12:21 AM

$SCNX Worth noting the latest update: SCNX now has GPO agreements giving access to 2,500+ hospitals, LTC facilities, and clinics on top of the PBM rebate covering 100M lives. That means Arbli isn’t just FDA-approved — it now has both commercial and institutional channels open. Of course, the real question is execution: will these deals turn into revenue fast enough? If Q3/Q4 filings show little income, dilution and possibly a reverse split are still on the table. That’s the bear case. On the flip side, the U.S. losartan market is $256M annually. Even a 10% penetration (~$25M) would be bigger than SCNX’s entire market cap today. With Rezenopy also FDA-approved, there’s more than one revenue driver here.

1 · Reply

BossLannisterTrades Oct. 2 at 2:18 AM

Looking for the next Monster runner?🚨🚨 Make sure you have ticker IVDA on ur watch. IVDA is Truly a gem of a ticker, known for big runs and perfect for a market like this where this can go on a massive rally of 400-500%+. IVDA has everything going for it, news/approved crypto treasury/Ai /Drone and most important of all it's a low float ticker. Be early bulls, because it will take off fast!! WATCHING: $WLDS $NVVE $SCNX $DKI

0 · Reply

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Aug 14, 2025, 9:00 AM EDT - 7 weeks ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 13, 2025, 8:05 AM EDT - 7 weeks ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Jul 24, 2025, 5:12 PM EDT - 2 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 16, 2025, 8:15 AM EDT - 2 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jun 17, 2025, 8:05 AM EDT - 3 months ago

Scienture Holdings Announces Cancelation of ELOC

May 28, 2025, 7:45 AM EDT - 4 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

May 22, 2025, 8:05 AM EDT - 4 months ago

SCIENTURE Announces Executive Leadership Transition

May 19, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

Apr 22, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 8, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 3, 2025, 8:26 AM EDT - 6 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Mar 25, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 19, 2025, 8:05 AM EDT - 7 months ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 18, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 6, 2025, 7:40 AM EST - 7 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Jan 21, 2025, 8:05 AM EST - 9 months ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Dec 17, 2024, 8:05 AM EST - 10 months ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 10, 2024, 8:05 AM EST - 10 months ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Jan 17, 2024, 9:07 AM EST - 1 year ago

Trxade health, Inc files its 3Q 10Q

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 8:35 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Jun 30, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

Jun 23, 2023, 4:40 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

Jun 23, 2023, 3:00 PM EDT - 2 years ago

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Jun 23, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

Jun 21, 2023, 12:36 PM EDT - 2 years ago

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

May 15, 2023, 10:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

May 15, 2023, 5:00 PM EDT - 2 years ago

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

May 5, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

Apr 25, 2023, 12:20 AM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

Mar 27, 2023, 9:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

PoFolks_Capital Oct. 6 at 11:57 PM

0 · Reply

APEDM Oct. 6 at 10:13 PM

$SCNX https://m.investing.com/news/sec-filings/scienture-holdings-amends-bylaws-to-lower-shareholder-meeting-quorum-93CH-4273967?ampMode=1

0 · Reply

Jhc1114 Oct. 6 at 6:11 PM

0 · Reply

Jhc1114 Oct. 6 at 5:41 PM

$SCNX I always warned whenever scammers promoted this here. So what was the result? A company that's like a cancer should disappear as soon as possible

0 · Reply

Jhc1114 Oct. 6 at 2:43 PM

0 · Reply

Et7806 Oct. 6 at 12:17 AM

$SCNX going to be a good week

0 · Reply

Dharmazen Oct. 5 at 12:28 AM

0 · Reply

Kickuraston Oct. 3 at 9:04 PM

$SCNX 8-K https://www.sec.gov/ix?doc=/Archives/edgar/data/0001382574/000149315225016882/form8-k.htm

1 · Reply

Orian1978 Oct. 3 at 12:21 AM

1 · Reply

BossLannisterTrades Oct. 2 at 2:18 AM

0 · Reply

BARCODES_ Oct. 2 at 12:09 AM

$SCNX news earlier

0 · Reply

PoFolks_Capital Oct. 1 at 4:10 PM

$SCNX when this finally moves up it better go to 30. This company has been the biggest investment mistake ive made. Deliberately beating on their investors.

1 · Reply

JackCampbell Oct. 1 at 2:13 PM

$SCNX very excited for q3 figures in November after all these great deals. Patience will always pay out!

0 · Reply

Jhc1114 Oct. 1 at 2:00 PM

$SCNX Let’s be clear — investors aren’t stupid. This is a zombie stock, and everyone knows it. Every time there's a flashy headline, it’s followed by another offering. They crush their own momentum. Check the filings — and protect your money.

2 · Reply

kenK2 Oct. 1 at 1:02 PM

$SCNX 💵💵🐏✅ come let’s get this shit back to 1.50

0 · Reply

MrTicker Oct. 1 at 1:02 PM

$SCNX SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions GLOBENEWSWIRE 8:00 AM ET 10/1/2025

0 · Reply

Bullish_Trader555 Oct. 1 at 12:50 PM

$SCNX Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions (SCNX)

0 · Reply

Adam_85 Oct. 1 at 12:48 PM

$SCNX Go Baby Go!

0 · Reply

PoFolks_Capital Sep. 30 at 9:58 PM

$SCNX im getting close to accepting the loss and moving on. Ive held since march and it's clear this company doesn't care about the long-term investors. Every decision they've made has had a negative impact. I know as soon as i sell it will go up though. If i hold it will prob continue down. They regained compliance and immediately dropped below a dollar again and they're about to lose compliance a second time. Idk im just sick of looking at their ticker at this point.

0 · Reply

Adam_85 Sep. 30 at 3:30 PM

$SCNX Where my Bulls at?

0 · Reply

Jhc1114 Sep. 29 at 4:03 PM

$SCNX Let’s think logically. This company’s financial situation is so dire that it needs to conduct offerings every month just to stay afloat. But seriously, who would buy this stock? To generate any meaningful revenue from its products, significant marketing efforts would be required. Yet, the company outsources everything — from manufacturing to promotion. Given this, is it really the right move to buy this stock? Scammers are getting paid marketing fees to help promote the company’s offerings. Don’t get caught up in it — let the company fail.

0 · Reply

BinaryLogic Sep. 27 at 5:08 PM

$SCNX [Execute] If/where the Company executes on Arbli in any real (material) capacity, the valuation should improve here (IMO) on a multiple from today. Again-start/build/add under $0.9 and/or keep on your watchlist for possible news/developments. Rezenopy + Arbli success (emphasis) creates 5X valuation improvement from these levels. https://www.stocktitan.net/news/SCNX/scienture-secures-pbm-led-gpo-rebate-agreement-to-drive-expanded-lkgihrecgiwn.html

0 · Reply

Market Cap	17.98M
Revenue (ttm)	140,000.00
Net Income (ttm)	9.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	6,478.57%
Debt to Equity Ratio	0.01

Volume	242,900
Avg Vol	372,554
Day's Range	N/A - N/A
Shares Out	20.75M
Stochastic %K	63%
Beta	3.11
Analysts	Strong Buy
Price Target	N/A